Martina Porter, MD

Pathway biology and new draining tunnel data shape how the panel positions TNF and IL-17 inhibitors. The discussion also makes the case that earlier treatment improves response and preserves functional tissue.

Medical and surgical management work in parallel in HS. The panel argues for treating through surgery on biologics and explains why de-roofing is within reach for community clinicians.

With three approved biologics, the choice of agent, the timing of initiation, and the definition of disease control all matter. The panel connects comorbidities, a simple screening question, and patient-reported outcomes to practical decisions.

Draining tunnels signal rapid progression and permanent scarring, shifting the urgency of treatment. The panel also identifies education gaps and the limits of static staging as the most pressing unmet needs.

Follicular occlusion, anaerobic biofilm, and innate immune activation combine to drive tissue destruction. The panel explains why tunnels sustain inflammation and mark the transition from acute disease to irreversible scarring.

Delayed recognition of HS costs patients time, tissue, and quality of life. The panel examines why episodic flares and atypical presentations are missed and the shame and isolation that follow.

STOP-HS1 and STOP-HS2 data show povorcitinib nearly doubled treatment response rates versus placebo in moderate to severe HS.

New STOP-HS trial data show durable povorcitinib response through week 54, with a favorable safety profile in hidradenitis suppurativa.

Martina Porter, MD, discusses new STOP-HS trial data on povorcitinib, the first oral phase 3 therapy for hidradenitis suppurativa.

54-week STOP-HS safety data for the JAK1-selective inhibitor povorcitinib showed no dose-dependent safety signal and few laboratory abnormalities.

54-week STOP-HS data show clinically meaningful improvements in pain, fatigue, and quality of life in one-third to two-thirds of patients.

Extension data through week 54 reveal deepening responses with povorcitinib in moderate-to-severe HS.

54-week data from the phase 3 STOP-HS1 and STOP-HS2 trials demonstrate JAK inhibitor povorcitinib's benefit in HS.

This interview highlights long-term, phase 3 data from the SUNSHINE and SUNRISE core and extension trials on secukinumab for hidradenitis suppurativa.

Panelists discuss how key research gaps include pediatric studies, understanding disease progression to enable early intervention, managing acute flares, addressing cosmetic concerns from scarring and hyperpigmentation, and highlight educational resources available through the HS Foundation, medical conferences, and specialized training programs.

Panelists discuss how the pipeline includes promising therapies like sonelokimab (an IL-17A/F nanobody with potential for better tissue penetration), various JAK inhibitors, IL-1α/β inhibitors, OX40 ligand blockers, and B-cell targeted therapies that may address disease heterogeneity and offer hope for patients with treatment-resistant disease.

Panelists discuss how they monitor patients through early follow-up visits at 1 to 3 months to assess medication access, manage cutaneous adverse effects, check liver function tests, and use educational handouts and pharmacy support to counsel patients on expected benefits vs risks while maintaining treatment adherence.

Panelists discuss how JAK inhibitors show promise for specific HS phenotypes, including patients with milder disease with inflammatory nodules, those with severe trunk/buttock disease, and systemically ill patients, and may work synergistically with IL-17 inhibitors in combination therapy for the most severe cases without additive infection risk.

Panelists discuss how secukinumab’s long-term data show sustained efficacy over 2 to 4 years with low immunogenicity, allowing patients to stop and restart therapy without loss of response—unlike TNF inhibitors—and demonstrate that some initial nonresponders improve significantly with extended treatment duration.

Panelists discuss how cutaneous adverse effects from IL-17 inhibitors, including eczematous rashes and fissures occurring in about 10% of patients, can be effectively managed with topical immunomodulators, antifungal prophylaxis, and patient counseling to maintain treatment adherence and prevent discontinuation.

Panelists discuss how 2-year bimekizumab data demonstrate that nearly half of patients achieve complete clearance (HiSCR100) with peak efficacy around 6 months, sustained improvement over time, and manageable safety concerns primarily involving cutaneous reactions like eczematous rashes that can be treated topically.

Panelists discuss how the 2 approved IL-17 inhibitors—secukinumab (IL-17A) and bimekizumab (IL-17A/F)—differ in their mechanisms, with bimekizumab potentially offering faster responses and greater impact on drainage but higher cutaneous adverse effects, while secukinumab provides a slightly better skin safety profile with slower but sustained improvement.

Panelists discuss how IL-17 emerged as a key inflammatory driver in HS pathophysiology, with IL-17 inhibitors offering strong efficacy and favorable safety profiles compared with TNF inhibitors, making them increasingly preferred as first-line biologic therapy except in patients with inflammatory bowel disease.

Panelists discuss how surgery plays a critical role in removing persistent draining sinus tunnels that don’t respond fully to anti-inflammatory medications, and explain their approach of combining biologics with surgical interventions rather than sequencing treatments, stacking therapies aggressively to achieve faster disease control.

Panelists discuss how treatment approaches vary by disease severity, with biologics becoming standard for patients with moderate to severe disease while milder cases receive antibiotics, hormonal therapies, and lifestyle interventions, emphasizing the need for flare management plans and patient education about treatment expectations.

Panelists discuss how societal factors like embarrassment and limited health care access contribute to diagnostic delays of 6 to 7 years despite HS being clinically straightforward to identify and describe the profound impact on patients’ lives beyond sterile quality of life measures, including loss of relationships, careers, and life milestones.

Panelists discuss how HS develops from a combination of genetic predisposition and environmental exposures, leading to immune-based inflammation in skin folds, and explain clinical diagnosis methods, including Hurley staging and assessment of inflammatory lesions.

In this set of interviews, 6 leaders in the field of dermatology highlight their experiences at the 2025 EADV Congress.

This discussion highlights 24-week findings on povorcitinib for those with moderate to severe hidradenitis suppurativa (HS).

In the fifth and final video from this series, experts discuss future research priorities and opportunities in hidradenitis suppurativa.